<DOC>
	<DOC>NCT00556296</DOC>
	<brief_summary>This study is designed to assess efficacy and safety of NRP-104 administered as a daily dose of 30mg, 50mg or 70mg compared to placebo in the treatment of children aged 6-12 years with ADHD.</brief_summary>
	<brief_title>Phase 3 Randomized Double-Blind Placebo-Controlled Study of NRP104 in Children Aged 6-12 With ADHD</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
	<criteria>primary diagnosis of ADHD combined subtype or the predominantly hyperactiveimpulsive subtype based on a psychiatric evaluation that reviews DSMIV criteria functioning at age appropriate levels intellectually blood pressure measurements within the 95th percentile for their gender, height and age ECG results are within the normal range comorbid psychiatric diagnosis (such as psychosis, bipolar illness, pervasive developmental disorder, severe obsessive compulsive disorder, severe depressive or severe anxiety disorder) or other symptomatic manifestations history of seizures (exclusive of febrile seizure), a tic disorder, or a family history of Tourette's disorder weighs less than 55 lbs (25 kg)or is significantly overweight or obese clinically significant ECG abnormality documented allergy or intolerance to amphetamines</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>